A delicate balance between rejection & BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients

PLoS ONE

Volumn 12, Issue 6, 2017, Pages

  Gard, Lilli ^a   Van Doesum, Willem ^a   Niesters, Hubert G M ^a   Van Son, Willem J ^a   Diepstra, Arjan ^a   Stegeman, Coen A ^a   Groen, Henk ^a   Riezebos Brilman, Annelies ^a,b   Sanders, Jan Stephan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BK POLYOMAVIRUS ASSOCIATED NEPHROPATHY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GENOTYPE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; MORTALITY RATE; OBSERVATIONAL STUDY; POLYOMAVIRUS INFECTION; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; VIREMIA; VIRUS LOAD; BK VIRUS; CHEMICALLY INDUCED; COMPLICATION; GENETICS; GRAFT REJECTION; HOST PATHOGEN INTERACTION; KAPLAN MEIER METHOD; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; VIROLOGY; VIRUS INFECTION;

ADULT; BK VIRUS; CYCLOSPORINE; FEMALE; GENOTYPE; GRAFT REJECTION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; OUTCOME ASSESSMENT (HEALTH CARE); POLYOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; TACROLIMUS; TRANSPLANT RECIPIENTS; TUMOR VIRUS INFECTIONS;

EID: 85020764308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0178801     Document Type: Article

References (44)

1. Hirsch HH, Vincenti F, Friman S, Tuncer M, Citterio F, Wiecek A, et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomizedmulticenter study. Am J Transplant. 2013; 13: 136-145. https://doi.org/10.1111/j.1600-6143.2012.04320.x PMID: 23137180.
2. Manitpisitkul W, Wilson NS, Haririan A. Immunosuppressive agents as risk factors for BK virus nephropathy: an overview and update. Expert Opin Drug Saf. 2010; 9: 959-969. https://doi.org/10.1517/14740338.2010.495714 PMID: 20521865.
3. Hirsch HH, Randhawa P, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013; 13 Suppl 4: 179-188.
4. Borni-Duval C, Caillard S, Olagne J, Perrin P, Braun-Parvez L, Heibel F, et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring. Transplantation. 2013; 95: 1498-1505. https://doi.org/10.1097/TP.0b013e3182921995 PMID: 23778568.
5. Pham PT, Reddy UG. Transplantation: Immunosuppression and risk of polyomavirus BK replication. Nat Rev Nephrol. 2013; 9: 135-136. https://doi.org/10.1038/nrneph.2013.17 PMID: 23399577.
6. Agha I, Brennan DC. BK virus and immunosuppressive agents. Adv Exp Med Biol. 2006; 577: 174-184. https://doi.org/10.1007/0-387-32957-9-12 PMID: 16626035.
7. Binet I, Nickeleit V, Hirsch HH, Prince O, Dalquen P, Gudat F, et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation. 1999; 67: 918-922. PMID: 10199744.
8. Manitpisitkul W, Drachenberg C, Ramos E, Munivenkatappa R, Philosophe B, Klassen D, et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. Transplantation. 2009; 88: 83-88. https://doi.org/10.1097/TP.0b013e3181aa8d93 PMID: 19584685.
9. Acott PD, O'Regan PA, Lee SH, Crocker JF. In vitro effect of cyclosporin A on primary and chronic BK polyoma virus infection in Vero E6 cells. Transpl Infect Dis. 2008; 10: 385-390. https://doi.org/10.1111/j.1399-3062.2008.00330.x PMID: 18665906.
10. Huang G, Chen LZ, Qiu J, Wang CX, Fei JG, Deng SX, et al. Prospective study of polyomavirus BK replication and nephropathy in renal transplant recipients in China: a single-center analysis of incidence, reduction in immunosuppression and clinical course. Clin Transplant. 2010; 24: 599-609. https://doi.org/10.1111/j.1399-0012.2009.01141.x PMID: 19925472.
11. Mengel M, Marwedel M, Radermacher J, Eden G, Schwarz A, Haller H, et al. Incidence of polyomavirus- nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant. 2003; 18: 1190-1196. PMID: 12748354.
12. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008; 8: 753-760. https://doi.org/10.1111/j.1600-6143.2008.02159.x PMID: 18294345.
13. Gard L, Niesters HG, Riezebos-Brilman A. A real time genotyping PCR assay for polyomavirus BK. J Virol Methods. 2015; 221: 51-56. https://doi.org/10.1016/j.jviromet.2015.04.024PMID: 25952730.
14. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem. 2005; 51: 1845-1853. https://doi.org/10.1373/clinchem.2005.052381 PMID: 16099939.
15. van der Meijden E, Kazem S, Burgers MM, Janssens R, Bouwes Bavinck JN, de Melker H, et al. Seroprevalence of trichodysplasia spinulosa-associated polyomavirus. Emerg Infect Dis. 2011; 17: 1355- 1363. https://doi.org/10.3201/eid1708.110114PMID: 21801610.
16. yV9 polyomaviruses found on the skin. PLoS One. 2013; 8: e81078. https://doi.org/10.1371/journal.pone.0081078 PMID: 24278381.
17. Schafer P, Tenschert W, Cremaschi L, Schroter M, Zollner B, Laufs R. Area under the viraemia curve versus absolute viral load: utility for predicting symptomatic cytomegalovirus infections in kidney transplant patients. J Med Virol. 2001; 65: 85-89. PMID: 11505448.
18. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002; 347: 488-496https://doi.org/10.1056/NEJMoa020439 PMID: 12181403.
19. Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation. 2009; 87: 1019-1026. https://doi.org/10.1097/TP.0b013e31819cc383 PMID: 19352121.
20. Schold JD, Rehman S, Kayle LK, Magliocca J, Srinivas TR, Meier-Kriesche HU. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int. 2009; 22: 626-634. https://doi.org/10.1111/j.1432-2277.2009.00842.x PMID: 19207187.
21. Naito T, Shinno K, Maeda T, Kagawa Y, Hashimoto H, Otsuka A, et al. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol Pharm Bull. 2006; 29: 275-280. PMID: 16462031.
22. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001; 23: 119-128. PMID: 11294511.
23. Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005; 5: 582-594. https://doi.org/10.1111/j.1600-6143.2005.00742.x PMID: 15707414.
24. Renner FC, Dietrich H, Bulut N, Celik D, Freitag E, Gaertner N, et al. The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune effects. Transplan t Proc. 2013; 45: 1608-1610. https://doi.org/10.1016/j.transproceed.2013.01.026 PMID: 23726630.
25. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357: 2562-2575. https://doi.org/10.1056/NEJMoa067411 PMID: 18094377.
26. Tholking G, Schmidt C, Koch R, Schuette-Nuetgen K, Pabst D, Wolters H, et al. Influence of tacrolimus metabolism rate on BKV infection after kidney transplantation. Sci Rep. 2016; 6: 32273. https://doi.org/10.1038/srep32273 PMID: 27573493.
27. Jouve T, Rostaing L, Malvezzi P. Place of mTOR inhibitors in management of BKV infection after kidney transplantation. J Nephropathol. 2016; 5: 1-7. https://doi.org/10.15171/jnp.2016.01 PMID: 27047803.
28. Hirsch HH, Yakhontova K, Lu M, Manzetti J. BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12. Am J Transplant. 2016; 16: 821-832. https://doi.org/10.1111/ajt.13541 PMID: 26639422.
29. Ali AM, Gibson IW, Birk P, Blydt-Hansen TD. Pretransplant serologic testing to identify the risk of polyoma BK viremia in pediatric kidney transplant recipients. Pediatr Transplant. 2011; 15: 827-834. https://doi.org/10.1111/j.1399-3046.2011.01583.x PMID: 22111998.
30. Randhawa P, Bohl D, Brennan D, Ruppert K, Ramaswami B, Storch G, et al. longitudinal analysis of levels of immunoglobulins against BK virus capsid proteins in kidney transplant recipients. Clin Vaccine Immunol. 2008; 15: 1564-1571. https://doi.org/10.1128/CVI.00206-08 PMID: 18753339.
31. Sood P, Senanayake S, Sujeet K, Medipalli R, Van-Why SK, Cronin DC, et al. Donor and recipient BKV-specific IgG antibody and posttransplantation BKV infection: a prospective single-center study. Transplantation. 2013; 95: 896-902. https://doi.org/10.1097/TP.0b013e318282ba83 PMID: 23511214.
32. Schwarz A, Linnenweber-Held S, Heim A, Framke T, Haller H, Schmitt C. Viral Origin, Clinical Course, and Renal Outcomes in Patients With BK Virus Infection After Living-Donor Renal Transplantation. Transplantation. 2016; 100: 844-853. https://doi.org/10.1097/TP.0000000000001066 PMID: 26720302.
33. Zhong S, Yogo Y, Ogawa Y, Oshiro Y, Fujimoto K, Kunitake T, et al. Even distribution of BK polyomavirus subtypes and subgroups in the Japanese Archipelago. Arch Virol. 2007; 152: 1613-1621. https://doi.org/10.1007/s00705-007-0997-y PMID: 17541698.
34. Krumbholz A, Zell R, Egerer R, Sauerbrei A, Helming A, Gruhn B, et al. Prevalence of BK virus subtype I in Germany. J Med Virol. 2006; 78: 1588-1598. https://doi.org/10.1002/jmv.20743PMID: 17063524.
35. Takasaka T, Goya N, Tokumoto T, Tanabe K, Toma H, Ogawa Y, et al. Subtypes of BK virus prevalent in Japan and variation in their transcriptional control region. J Gen Virol. 2004; 85: 2821-2827. https://doi.org/10.1099/vir.0.80363-0 PMID: 15448343.
36. Egli A, Kohli S, Dickenmann M, Hirsch HH. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. Transplantation. 2009; 88: 1161-1168. https://doi.org/10.1097/TP.0b013e3181bca422 PMID: 19935369.
37. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl. 2006; 12: 51-57. https://doi.org/10.1002/lt.20532 PMID: 16382464.
38. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun. 2004; 313: 42-47. PMID: 14672695.
39. Vahlne A, Larsson PA, Horal P, Ahlmen J, Svennerholm B, Gronowitz JS, et al. Inhibition of herpes simplex virus production in vitro by cyclosporin A. Arch Virol. 1992; 122: 61-75. PMID: 1309645.
40. Li YJ, Weng CH, Lai WC, Wu HH, Chen YC, Hung CC, et al. A suppressive effect of cyclosporine A on replication and noncoding control region activation of polyomavirus BK virus. Transplantation. 2010; 89: 299-306. https://doi.org/10.1097/TP.0b013e3181c9b51c PMID: 20145520.
41. Benavides CA, Pollard VB, Mauiyyedi S, Podder H, Knight R, Kahan BD. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation. 2007; 84: 83-88. https://doi.org/10.1097/01.tp.0000268524.27506.39 PMID: 17627242.
42. Sanchez Fructuoso AI, Calvo N, Perez-Flores I, Valero R, Rodriguez-Sanchez B, Garcia de Viedma D, et al. Mammalian target of rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients. Transpl Infect Dis. 2011; 13: 584-591. https://doi.org/10.1111/j.1399-3062.2011.00649.x PMID: 21585634.
43. Polanco N, Gonzalez Monte E, Folgueira MD, Morales E, Gutierrez Martinez E, Bengoa I, et al. Everolimus- based immunosuppression therapy for BK virus nephropathy. Transplant Proc. 2015; 47: 57-61. https://doi.org/10.1016/j.transproceed.2014.11.008PMID: 25645770.
44. Wali RK, Drachenberg C, Hirsch HH, Papadimitriou J, Nahar A, Mohanlal V, et al. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation. 2004; 78: 1069-1073. PMID: 15480176.